Search

In this work, a series of C60/C70 fullerene derivatives bearing non-aromatic and mono-, bi-, tri- and tetracyclic aryl-substituents was synthesized according to the modified Bingel method and characterized using spectral methods: ESI-MS, 1H NMR, 13C NMR, UV–Vis, FT-IR and cyclic voltammetry (CV). HOMO and LUMO energy levels and the band gaps for optimized structures of reported fullerene derivatives were determined according to the DFT functionals, B3LYP 6-31G(d) and PBE/6-311G(d,p). Results obtained from CV and UV–Vis measurements, which showed very good agreement, were compared to calculated theoretical values also revealing satisfactory level of compliance of the obtained results. We have studied the impact of presence and number of aromatic rings in malonate substituent of C60/C70 fullerene derivatives employed as acceptor materials on performance of BHJ solar cells prepared using PTB7-Th as donor material. We successfully prepared solar cells based on all the synthesized compounds, and the highest performance of the obtained photovoltaic devices was observed for fullerene derivatives bearing monocyclic and bicyclic aromatic moieties. The obtained voltage was about 0.8 V and current density was above 10 mA/cm2. Optical studies showed absorption edges at 1.9 eV and 1.8 eV for C60 and C70 derivatives, respectively, with absorption coefficients comparable to C60/C70 PCBM samples. Photocurrent spectroscopy showed 20–40% quantum efficiency. Long-term ageing measurements showed T80 time between 105 days and 115 days for derivatives with phenyl and naphthalene substituents. Taking into account that synthesis of reported fullerene derivatives is very convenient, the reported compounds are very promising materials for construction of BHJ solar cells. [ABSTRACT FROM AUTHOR]

Graphene functionalized with dianthracene malonate was synthesized and used subsequently for construction of covalently bound graphene-fullerene hybrid nanomaterials. For this purpose, novel approach of Diels–Alder reaction of C60/C70 fullerene cores with anthracene moieties previously introduced onto graphene surface was successfully employed. Structure and composition of obtained graphene and its derivatives were characterized using scanning electron microscopy (SEM), X-ray photoelectron spectroscopy (XPS) and FT-IR spectroscopy. Obtained results revealed that both C60 and C70 fullerenes were found to be capable of formation desired Diels–Alder adducts, yielding products of different morphology. Capacitive properties of the synthesized energy storage nanomaterials were determined by means of cyclic voltammetry (CV) and galvanostatic charge/discharge (GCD) measurements, revealing that functionalization of graphene with C60 moieties enhances its energy storage properties. [ABSTRACT FROM AUTHOR]

CTEMPO catalytic system linked to a microspherical gold support through a covalent S-Au bond was developed. The CTEMPO@Au composite catalyst had a particle size of 0.5-0.8 μm and was covered with the fullerenes derivative of 2.3 nm diameter bearing ten nitroxyl groups; the organic film showed up to 50 nm thickness. The catalytic composite allowed for the oxidation under mild conditions of various primary and secondary alcohols to the corresponding aldehyde and ketone analogues with efficiencies as high as 79-98%, thus giving values typical for homogeneous catalysis, while retaining at the same time all the advantages of heterogeneous catalysis, e.g., easy separation by filtration from the reaction mixture. The catalytic activity of the resulting system was studied by means of high pressure liquid chromatography. A redox mechanism was proposed for the process. In the catalytic cycle of the oxidation process, the TEMPO moiety was continuously regenerated in situ with an applied primary oxidant, for example, O/Fe system. The new intermediate composite components and the final catalyst were characterized by various spectroscopic methods and thermogravimetry. [ABSTRACT FROM AUTHOR]

This study describes warm spells in Northern Europe and determines the synoptic situations that cause their occurrence. In this article, a relatively warm day was defined as a day when the maximum temperature exceeded the 95th annual percentile, and a warm spell (WS) was considered to be a sequence of at least five relatively warm days. In the analysed multiannual period and within the investigated area, 24 (Kallax) to 53 (Oslo) WSs were observed. The occurrence of WSs was mainly connected with positive anomalies of sea level pressure and a 500-hPa isobaric surface, displaying the presence of high-pressure systems. This occurrence was also accompanied by positive T850 anomalies. [ABSTRACT FROM AUTHOR]

There are several studies on the association of TLR9 polymorphisms with systemic lupus erythematosus (SLE) in different ethnicities; however, the results are inconsistent. Therefore, we studied the distribution of the TLR9 C > T (rs352140) polymorphism in patients with SLE ( n = 254) and controls ( n = 521) in a Polish population. We did not observe significant differences in the prevalence of the TLR9 C > T genotype and alleles between patients with SLE and controls. However, we found a contribution of the T/T and T/C genotypes to renal [OR = 2.949 (95 % CI = 1.523-5.711, p = 0.001), ( p = 0.017)] and immunologic disorders [OR = 2.938 (95 % CI 1.500-5.755, p = 0.0012), ( p = 0.0204)] in SLE patients. Moreover, we observed a significant association between the TLR9 T/T and T/C genotypes and the presence of anti-dsDNA Ab [OR = 3.682 (1.647-8.230, p = 0.001), ( p = 0.017)]. Our studies suggest that the TLR9 C > T (rs352140) polymorphism might contribute to renal and immunologic disorders and to the presence of anti-dsDNA Ab. [ABSTRACT FROM AUTHOR]

The STAT4 has been found to be a susceptible gene in the development of systemic lupus erythematosus (SLE) in various populations. There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population. We found that patients with the STAT4 C/G and CC genotypes exhibited a 1.583-fold increased risk of SLE incidence (95 % CI = 1.168-2.145, p = 0.003), with OR for the C/C versus C/G and G/G genotypes was 1.967 (95 % CI = 1.152-3.358, p = 0.0119). The OR for the STAT4 C allele frequency showed a 1.539-fold increased risk of SLE (95 % CI = 1.209-1.959, p = 0.0004). We also observed an increased frequency of STAT4 C/C and C/G genotypes in SLE patients with renal symptoms OR = 2.259 (1.365-3.738, p = 0.0014), ( p = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), ( p = 0.0272). Moreover, we found a contribution of STAT4 C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), ( p = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), ( p = 0.0476). Our studies confirmed an association of the STAT4 C (rs7582694) variant with the development of SLE and occurrence of some clinical manifestations of the disease. [ABSTRACT FROM AUTHOR]

Multiple studies have indicated that SLE incidence exhibits a strong genetic background. We studied the frequency of the natural killer group 2, member D ( NKG2D) receptor Thr72Ala (rs2255336) polymorphism in patients with SLE ( n = 243) and controls ( n = 502) in a sample of the Polish population. The p value for SLE patients with the Thr/Thr genotype was 0.0455 and Odds Ratio (OR) = 0.3846 (95% CI = 0.1458-1.014). For the Thr/Thr and Ala/Thr genotypes we found p = 0.0135 and OR = 0.6556 (95% CI = 0.4684-0.9177). The frequency of the NKG2D 72Thr allele in patients and controls was respectively, 15 and 21%, P = 0.0046, OR = 0.6547 (95% CI = 0.4877-0.8789). Our studies may confirm that the NKG2D 72Thr gene variant may protect against the incidence of SLE. [ABSTRACT FROM AUTHOR]

Abstract  Endogenous sex hormones have been observed to have a role in systemic lupus erythematosus (SLE) predisposition. Sex hormone-binding globulin (SHBG) regulates the bioavailability of sex hormones to target tissues. Therefore, we examined the distribution of the SHBG functional polymorphism Asp327Asn (rs6259) in SLE patients (n = 150) and controls (n = 150) in a Polish population. We found a contribution of the SHBG327Asn variant to the development of SLE. Women with the Asp/Asn and Asn/Asn genotypes displayed a 2.630-fold increased risk of SLE (95% CI = 1.561–4.433, P = 0.0003). SHBG has a much higher affinity for testosterone than estradiol, and the SHBG327Asn variant displays a reduction of estradiol clearance. Therefore we suggest that the opposing effects of estrogens and testosterone on the immune system and imbalance in the levels of these hormones in SLE patients can be enhanced by the SHBG327Asn protein variant. [ABSTRACT FROM AUTHOR]

The transcription of human endogenous retrovirus E (HERV-E) clone 4-1 was determined in peripheral blood mononuclear cells (PBMC) of patients with systemic lupus erythematosus (SLE). However, the contribution of HERV-E clone 4-1 expression in the development of SLE remains unclear. Blood plasma and PBMC from 55 patients with SLE and a control group of 35 healthy individuals were collected. Blood plasma concentration of five antinuclear antibodies including anti-U1 ribonucleoprotein (RNP), anti-Sm, anti-Scl-70, anti-single-stranded DNA (ssDNA), and anti-double-stranded DNA (dsDNA) was analyzed by enzyme-linked immunosorbent assay (ELISA). Total RNA was isolated from PBMC and reverse transcribed into cDNA. The number of copies of HERV-E clone 4-1 gag transcript in PBMC was determined by real-time quantitative polymerase chain reaction (RQ-PCR) analysis. Spearman statistical analysis indicated that blood plasma concentrations of anti-U1 RNP and anti-Sm antibodies may correlate with PBMC transcript levels of HERV-E clone 4-1 gag sequence ( R=0.775, p<0.000001; R=0.698, p<0.000001, respectively). Our observations suggest that the expression of HERV-E clone 4-1 might be associated with production of anti-U1 RNP and anti-Sm antibodies in patients with SLE. [ABSTRACT FROM AUTHOR]